Voisard Asset Management Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Voisard Asset Management Group’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-270	Closed	-$773	–	708
2024 Q3	$773	Hold	270	–	–	﹤0.01%	490
2024 Q2	$789	Hold	270	–	–	﹤0.01%	359
2024 Q1	$862	Hold	270	–	–	﹤0.01%	333
2023 Q4	$908	Buy	+270	New	+$696	﹤0.01%	356

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Voisard Asset Management Group's PSTX Position: Q4 2024 in Review

Voisard Asset Management Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 270 shares — an estimated $773 sold.

Voisard Asset Management Group first reported a position in PSTX in Q4 2023 and held it in 4 quarters. The position peaked at $908 in Q4 2023. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Voisard Asset Management Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Voisard Asset Management Group sold 270 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $773.
Voisard Asset Management Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2023 and held it in 4 quarters.
Voisard Asset Management Group's Poseida Therapeutics, Inc. Common Stock position peaked at $908 in Q4 2023.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.